Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients

Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients

In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of f...

Full description

Bibliographic Details
Main Authors: F.A. Cadegiani, A. Goren, C.G. Wambier, J. McCoy
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:New Microbes and New Infections
Subjects:
Antiandrogen
clinical equipoise
COVID-19
dutasteride
hydroxychloroquine
ivermectin
Online Access:http://www.sciencedirect.com/science/article/pii/S2052297521000792

Internet

http://www.sciencedirect.com/science/article/pii/S2052297521000792

Similar Items